Please assess the completion status of the following clinical trial:

Trial Title: Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of cystic fibrosis~* Early lower respiratory tract infection with P. aeruginosa,~Exclusion Criteria:~* Known local or systemic hypersensitivity to aminoglycosides or inhaled antibiotics.~* Administration of loop diuretics within 7 days prior to study drug administration.~* Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 3 Months
- Maximum Age: 6 Years
- Healthy Volunteers: f

Study Arms:
- TOBI (tobramycin inhaled solution)/Placebo (Type: EXPERIMENTAL): Participants randomized to TOBI received the investigational treatment for 28 days twice daily (bi)d in the first treatment cycle. At the end of first treatment cycle, participants who were positive for P. aeruginosa entered the open label (OL) phase of the study and received TOBI for 28 days bid. Participants who were negative for P. aeruginosa at the end of first treatment cycle and agreed to participate in the cross-over treatment period received placebo for 28 days bid (second treatment cycle).
- Placebo/TOBI (Type: PLACEBO_COMPARATOR): Participants randomized to placebo group received 0.9 % saline (NaCl) for 28 days bid in the first treatment cycle. At the end of first treatment cycle, participants who were positive for P. aeruginosa entered the OL phase of the study and received TOBI for 28 days bid. Participants who were negative for P. aeruginosa at the end of first treatment cycle and agreed to participate in the cross-over treatment period received TOBI for 28 days bid (second treatment cycle).

Based on this trial design, predict the completion outcome and termination type (if applicable).